233 related articles for article (PubMed ID: 35582833)
21. Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data.
Daoud M; Suppa M; Benhadou F; Daxhelet M; Njimi H; White J; Jemec G; Del Marmol V
Front Med (Lausanne); 2023; 10():1145152. PubMed ID: 37138732
[TBL] [Abstract][Full Text] [Related]
22. Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa.
Kirby JS; Hereford B; Thorlacius L; Villumsen B; Ingram JR; Garg A; Butt M; Esmann S; King T; Tan J; Jemec GBE
Br J Dermatol; 2021 Apr; 184(4):681-687. PubMed ID: 32602129
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial.
Ben Abdallah H; Bregnhøj A; Emmanuel T; Ghatnekar G; Johansen C; Iversen L
JAMA Dermatol; 2024 Jan; 160(1):63-70. PubMed ID: 38055242
[TBL] [Abstract][Full Text] [Related]
24. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
25. Severity and Area Score for Hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa.
Kirby JS; Butt M; King T
Br J Dermatol; 2020 Apr; 182(4):940-948. PubMed ID: 31233623
[TBL] [Abstract][Full Text] [Related]
26. Could Residents Adequately Assess the Severity of Hidradenitis Suppurativa? Interrater and Intrarater Reliability Assessment of Major Scoring Systems.
Włodarek K; Stefaniak A; Matusiak Ł; Szepietowski JC
Dermatology; 2020; 236(1):8-14. PubMed ID: 31487719
[TBL] [Abstract][Full Text] [Related]
27. Development of HiSQOL: A Hidradenitis Suppurativa-Specific Quality of Life Instrument.
Thorlacius L; Esmann S; Miller I; Vinding G; Jemec GBE
Skin Appendage Disord; 2019 Jun; 5(4):221-229. PubMed ID: 31367600
[TBL] [Abstract][Full Text] [Related]
28. Patient-reported outcomes in hidradenitis suppurativa.
Vellaichamy G; Braunberger TL; Jones JL; Peacock A; Nahhas AF; Hamzavi IH
G Ital Dermatol Venereol; 2019 Apr; 154(2):137-147. PubMed ID: 30375207
[TBL] [Abstract][Full Text] [Related]
29. Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus Statement.
Mastacouris N; Tannenbaum R; Strunk A; Koptyev J; Aarts P; Alhusayen R; Bechara FG; Benhadou F; Bettoli V; Brassard A; Brown D; Choon SE; Coutts P; da Silva DLF; Daveluy S; Dellavalle RP; Del Marmol V; Emtestam L; Gebauer K; George R; Giamarellos-Bourboulis EJ; Goldfarb N; Hamzavi I; Hazen PG; Horváth B; Hsiao J; Ingram JR; Jemec GBE; Kirby JS; Lowes MA; Marzano AV; Matusiak L; Naik HB; Okun MM; Oon HH; Orenstein LAV; Paek SY; Pascual JC; Fernandez-Peñas P; Resnik BI; Sayed CJ; Thorlacius L; van der Zee HH; van Straalen KR; Garg A
JAMA Dermatol; 2023 Nov; 159(11):1258-1266. PubMed ID: 37755725
[TBL] [Abstract][Full Text] [Related]
30. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
[TBL] [Abstract][Full Text] [Related]
31. Measuring Quality of Life in Hidradenitis Suppurativa: Development and Validation of a Disease-specific Patient-reported Outcome Measure for Practice and Research.
Otten M; Augustin M; Blome C; Topp J; Niklaus M; Hilbring C; Bechara FG; Pinter A; Zouboulis CC; Anzengruber F; Kirsten N
Acta Derm Venereol; 2023 Jan; 103():adv00859. PubMed ID: 36129249
[TBL] [Abstract][Full Text] [Related]
32. A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa.
Jepsen R; Edwards C; Flora A; Kozera E; Frew JW
J Am Acad Dermatol; 2023 Oct; 89(4):694-702. PubMed ID: 37307994
[TBL] [Abstract][Full Text] [Related]
33. Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.
Kimball AB; Tzellos T; Calimlim BM; Teixeira HD; Geng Z; Okun MM
Acta Derm Venereol; 2018 Nov; 98(10):932-937. PubMed ID: 30085324
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of radiofrequency in the treatment of hidradenitis suppurativa; a systematic review.
Nilforoushzadeh MA; Heidari N; Heidari A; Ghane Y; Hosseini S; Lotfi Z; Jaffary F; Nobari MN; Aghamiri ZS; Nobari NN
Lasers Med Sci; 2024 May; 39(1):139. PubMed ID: 38795173
[TBL] [Abstract][Full Text] [Related]
35. Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation.
Caposiena Caro RD; Molinelli E; Brisigotti V; Offidani A; Bianchi L
Clin Exp Dermatol; 2021 Jan; 46(1):96-102. PubMed ID: 32683727
[TBL] [Abstract][Full Text] [Related]
36. Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice.
Montero-Vilchez T; Salvador-Rodriguez L; Sanchez-Diaz M; Cuenca-Barrales C; Martinez-Lopez A; Arias-Santiago S; Molina-Leyva A
Dermatol Ther; 2020 Nov; 33(6):e14254. PubMed ID: 32860480
[TBL] [Abstract][Full Text] [Related]
37. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process.
Thorlacius L; Ingram JR; Villumsen B; Esmann S; Kirby JS; Gottlieb AB; Merola JF; Dellavalle R; Nielsen SM; Christensen R; Garg A; Jemec GBE;
Br J Dermatol; 2018 Sep; 179(3):642-650. PubMed ID: 29654696
[TBL] [Abstract][Full Text] [Related]
38. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment.
Rondags A; van Straalen KR; van Hasselt JR; Janse IC; Ardon CB; Vossen ARJV; Prens EP; van der Zee HH; Horváth B
Br J Dermatol; 2019 May; 180(5):1214-1220. PubMed ID: 30512186
[TBL] [Abstract][Full Text] [Related]
39. LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Results from Period A of RELIEVE, a Multicenter Randomized, Controlled Trial.
Schultheis M; Staubach P; Nikolakis G; Grabbe S; Ruckes C; von Stebut E; Kirschner U; Matusiak Ł; Szepietowski JC
Dermatology; 2022; 238(3):476-486. PubMed ID: 34535610
[TBL] [Abstract][Full Text] [Related]
40. Azathioprine in hidradenitis suppurativa with inflammatory phenotype: a case series of 11 patients.
López Riquelme I; Fernández Ballesteros MD; Perea Polak A; Serrano Ordoñez A; Martínez Pilar L
Int J Dermatol; 2023 Oct; 62(10):1300-1303. PubMed ID: 37548251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
